Abstract
The rapidly accruing literature on Sandostatin indicates that it may be effective outside its current area of application, the treatment of symptomatic endocrine tumors of the GEP system. The following brief remarks and suggested future directions for Sandostatin represent ideas and comments from clinical research protocols and from reports on special applications presented in either abstract or publication form.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer Verlag, Berlin Heidelberg
About this paper
Cite this paper
O’Dorisio, T.M. (1989). Future Directions. In: O’Dorisio, T.M. (eds) Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61328-9_16
Download citation
DOI: https://doi.org/10.1007/978-3-642-61328-9_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64794-9
Online ISBN: 978-3-642-61328-9
eBook Packages: Springer Book Archive